142 related articles for article (PubMed ID: 36960626)
1. Clinical Outcome of Stereotactic Body Radiotherapy in Patients with Early-Stage Lung Cancer with Ground-Glass Opacity Predominant Lesions: A Single Institution Experience.
Jang JY; Kim SS; Song SY; Shin YS; Lee SW; Ji W; Choi CM; Choi EK
Cancer Res Treat; 2023 Oct; 55(4):1181-1189. PubMed ID: 36960626
[TBL] [Abstract][Full Text] [Related]
2. Never too old: A single-institution experience of stereotactic body radiation therapy for patients 90 years and older with early stage lung cancer.
Videtic GMM; Woody NM; Reddy CA; Stephans KL
Pract Radiat Oncol; 2017; 7(6):e543-e549. PubMed ID: 28867545
[TBL] [Abstract][Full Text] [Related]
3. CT Findings and Treatment Outcomes of Ground-Glass Opacity Predominant Lung Cancer After Stereotactic Body Radiotherapy.
Mikami N; Takeda A; Hashimoto A; Takeda T; Kimura Y; Oku Y; Aoki Y; Eriguchi T; Tsurugai Y; Saeki N; Enomoto T; Kuribayashi H; Masuda M; Kaneko T
Clin Lung Cancer; 2022 Jul; 23(5):428-437. PubMed ID: 35637134
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy in patients with lung tumors composed of mainly ground-glass opacity.
Onishi H; Shioyama Y; Matsumoto Y; Shibamoto Y; Miyakawa A; Suzuki G; Nishimura Y; Sasaki R; Miyawaki D; Kuriyama K; Komiyama T; Marino K; Aoki S; Saito R; Araya M; Maehata Y; Nonaka H; Tominaga L; Saito M; Sano N; Yamada S
J Radiat Res; 2020 May; 61(3):426-430. PubMed ID: 32219316
[TBL] [Abstract][Full Text] [Related]
5. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non-Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution.
Abreu CECV; Moraes FY; Miranda FA; Siqueira GSM; Gadia R; Haddad CK; Carvalho HA
J Glob Oncol; 2018 Jul; 4():1-8. PubMed ID: 30085881
[TBL] [Abstract][Full Text] [Related]
7. 30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer.
Videtic GM; Stephans KL; Woody NM; Reddy CA; Zhuang T; Magnelli A; Djemil T
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):203-8. PubMed ID: 25015198
[TBL] [Abstract][Full Text] [Related]
8. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.
Bradley JD; El Naqa I; Drzymala RE; Trovo M; Jones G; Denning MD
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1146-50. PubMed ID: 19800181
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial.
Timmerman RD; Paulus R; Pass HI; Gore EM; Edelman MJ; Galvin J; Straube WL; Nedzi LA; McGarry RC; Robinson CG; Schiff PB; Chang G; Loo BW; Bradley JD; Choy H
JAMA Oncol; 2018 Sep; 4(9):1263-1266. PubMed ID: 29852037
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.
Taremi M; Hope A; Dahele M; Pearson S; Fung S; Purdie T; Brade A; Cho J; Sun A; Bissonnette JP; Bezjak A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):967-73. PubMed ID: 21377293
[TBL] [Abstract][Full Text] [Related]
14. Effect of Tumor Location and Dosimetric Predictors for Chest Wall Toxicity in Single-Fraction Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
Manyam BV; Videtic GMM; Verdecchia K; Reddy CA; Woody NM; Stephans KL
Pract Radiat Oncol; 2019 Mar; 9(2):e187-e195. PubMed ID: 30529796
[TBL] [Abstract][Full Text] [Related]
15. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer.
Ma SJ; Serra LM; Syed YA; Hermann GM; Gomez-Suescun JA; Singh AK
Clin Lung Cancer; 2018 Mar; 19(2):e235-e240. PubMed ID: 29153897
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?
Onishi H; Shirato H; Nagata Y; Hiraoka M; Fujino M; Gomi K; Karasawa K; Hayakawa K; Niibe Y; Takai Y; Kimura T; Takeda A; Ouchi A; Hareyama M; Kokubo M; Kozuka T; Arimoto T; Hara R; Itami J; Araki T
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1352-8. PubMed ID: 20638194
[TBL] [Abstract][Full Text] [Related]
18. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.
Takeda A; Kunieda E; Fujii H; Yokosuka N; Aoki Y; Oooka Y; Oku Y; Ohashi T; Sanuki N; Mizuno T; Ozawa Y
Lung Cancer; 2013 Mar; 79(3):248-53. PubMed ID: 23246123
[TBL] [Abstract][Full Text] [Related]
19. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes and Safety Profile in the Treatment of Synchronous Nonmetastatic Lung Tumors With Stereotactic Body Radiation Therapy.
Raju SC; Peters GW; Decker RH; Park HS
Pract Radiat Oncol; 2022; 12(2):e110-e116. PubMed ID: 34861443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
